Y-mAbs Therapeutics, Inc. financial data

Symbol
YMAB on Nasdaq
Industry
Pharmaceutical Preparations
Location
230 Park Avenue, Suite 3350, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 418 % -13.6%
Quick Ratio 29.6 % +6.35%
Debt-to-equity 33.1 % +17.8%
Return On Equity -24.6 % -34.6%
Return On Assets -18.5 % -29.6%
Operating Margin -33.7 % -32.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.8M shares +2.68%
Common Stock, Shares, Outstanding 44.8M shares
Entity Public Float 246M USD -55.4%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 44.6M shares +2.31%
Weighted Average Number of Shares Outstanding, Diluted 44.6M shares +2.31%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 84.6M USD -8.99%
Research and Development Expense 50.2M USD -17.2%
Costs and Expenses 113M USD -3.02%
Operating Income (Loss) -28.5M USD -20.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -23.1M USD -21.9%
Income Tax Expense (Benefit) 801K USD +119%
Net Income (Loss) Attributable to Parent -23.9M USD -23.8%
Earnings Per Share, Basic -0.54 USD/shares -20%
Earnings Per Share, Diluted -0.54 USD/shares -20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68.1M USD -21.3%
Accounts Receivable, after Allowance for Credit Loss, Current 19.9M USD +5.52%
Inventory, Net 9.56M USD +34.4%
Other Assets, Current 1.46M USD -36.5%
Assets, Current 99.1M USD -13.8%
Property, Plant and Equipment, Net 53K USD -82.1%
Operating Lease, Right-of-Use Asset 1.08M USD -32.5%
Intangible Assets, Net (Excluding Goodwill) 2.37M USD -13%
Other Assets, Noncurrent 18.4M USD +95.1%
Assets 121M USD -6.18%
Accounts Payable, Current 7.88M USD +3.52%
Accrued Liabilities, Current 16.6M USD +25.1%
Liabilities, Current 25.3M USD +16%
Operating Lease, Liability, Noncurrent 299K USD -58.8%
Other Liabilities, Noncurrent 897K USD +9.12%
Liabilities 28.5M USD -0.86%
Accumulated Other Comprehensive Income (Loss), Net of Tax -36K USD -102%
Retained Earnings (Accumulated Deficit) -480M USD -5.23%
Stockholders' Equity Attributable to Parent 92.4M USD -7.71%
Liabilities and Equity 121M USD -6.18%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.48M USD +73.5%
Net Cash Provided by (Used in) Financing Activities 588K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 44.8M shares +2.63%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.89M USD +78%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 68.1M USD -21.3%
Deferred Tax Assets, Valuation Allowance 149M USD +4.49%
Operating Lease, Liability 1.08M USD -33.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.7M USD -16.3%
Lessee, Operating Lease, Liability, to be Paid 1.15M USD -34.3%
Operating Lease, Liability, Current 776K USD -13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 187K USD -63.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 698K USD -28.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 76K USD -41.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16K USD
Deferred Tax Assets, Operating Loss Carryforwards 83.2M USD -3.29%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 346K USD +85%
Preferred Stock, Shares Authorized 5.5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.01M USD -27.3%
Additional Paid in Capital 573M USD +3.25%
Depreciation, Depletion and Amortization 159K USD -12.6%
Share-based Payment Arrangement, Expense 4.2M USD +74.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%